Remdesivir and mortality reduction in COVID-19 patients: a systematized subgroup analysis of clinical trials

Remdesivir and mortality reduction in COVID-19 patients: a systematized subgroup analysis of clinical trials

<p><strong>Objective:</strong> Remdesivir has not shown survival benefit for patients with severe COVID-19. However, subgroup analysis of ACTT-1 Study Group showed an apparent reduction in mortality for patients who required non?high-flow oxygen. Presentation of SOLIDARITY study...

Full description

Bibliographic Details
Main Authors: Emilio Jesús Alegre-del Rey, Manuel David Gil-Sierra, Catalina Alarcón de la Lastra-Romero, Marina Sánchez-Hidalgo
Format: Article
Language:English
Published: Grupo Aula Médica 2021-01-01
Series:Farmacia Hospitalaria
Subjects:
remdesivir
covid-19 drug treatment
data interpretation
statistical
treatment outcome
drug evaluation
mortality
assessment
outcomes
Online Access:http://www.aulamedica.es/fh/pdf/11591.pdf

Internet

http://www.aulamedica.es/fh/pdf/11591.pdf

Similar Items